Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2006 Apr;7(4):360-70.

GW-501516 GlaxoSmithKline/Ligand.

Author information

1
Johnson & Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Raritan, NJ 08869, USA. PPelton@prdus.jnj.com

Abstract

GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Phase II clinical trials of this compound are ongoing.

PMID:
16625823
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center